Switch theme
Sign up to access all valuation multiples
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
1999
829
LTM Revenue $1.5B
LTM EBITDA $512M
$17.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zhangzhou Pientzehuang has a last 12-month revenue (LTM) of $1.5B and a last 12-month EBITDA of $512M.
In the most recent fiscal year, Zhangzhou Pientzehuang achieved revenue of $1.5B and an EBITDA of $510M.
Zhangzhou Pientzehuang expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhangzhou Pientzehuang valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Profit | $659M | XXX | $640M | XXX | XXX | XXX |
| Gross Margin | 43% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $512M | XXX | $510M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $505M | XXX | $478M | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $427M | XXX | $413M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zhangzhou Pientzehuang's stock price is CNY 204 (or $28).
Zhangzhou Pientzehuang has current market cap of CNY 123B (or $17.1B), and EV of CNY 123B (or $17.0B).
See Zhangzhou Pientzehuang trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.0B | $17.1B | XXX | XXX | XXX | XXX | $0.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zhangzhou Pientzehuang has market cap of $17.1B and EV of $17.0B.
Zhangzhou Pientzehuang's trades at 11.4x EV/Revenue multiple, and 33.5x EV/EBITDA.
Equity research analysts estimate Zhangzhou Pientzehuang's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhangzhou Pientzehuang has a P/E ratio of 40.0x.
See valuation multiples for Zhangzhou Pientzehuang and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.1B | XXX | $17.1B | XXX | XXX | XXX |
| EV (current) | $17.0B | XXX | $17.0B | XXX | XXX | XXX |
| EV/Revenue | 11.0x | XXX | 11.4x | XXX | XXX | XXX |
| EV/EBITDA | 33.3x | XXX | 33.5x | XXX | XXX | XXX |
| EV/EBIT | 33.8x | XXX | 35.7x | XXX | XXX | XXX |
| EV/Gross Profit | 25.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 40.0x | XXX | 41.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 500.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZhangzhou Pientzehuang's last 12 month revenue growth is 9%
Zhangzhou Pientzehuang's revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $0.2M for the same period.
Zhangzhou Pientzehuang's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zhangzhou Pientzehuang's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zhangzhou Pientzehuang and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 44% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhangzhou Pientzehuang acquired XXX companies to date.
Last acquisition by Zhangzhou Pientzehuang was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhangzhou Pientzehuang acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zhangzhou Pientzehuang founded? | Zhangzhou Pientzehuang was founded in 1999. |
| Where is Zhangzhou Pientzehuang headquartered? | Zhangzhou Pientzehuang is headquartered in China. |
| How many employees does Zhangzhou Pientzehuang have? | As of today, Zhangzhou Pientzehuang has 829 employees. |
| Is Zhangzhou Pientzehuang publicy listed? | Yes, Zhangzhou Pientzehuang is a public company listed on SHG. |
| What is the stock symbol of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang trades under 600436 ticker. |
| When did Zhangzhou Pientzehuang go public? | Zhangzhou Pientzehuang went public in 2003. |
| Who are competitors of Zhangzhou Pientzehuang? | Similar companies to Zhangzhou Pientzehuang include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's current market cap is $17.1B |
| What is the current revenue of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's last 12 months revenue is $1.5B. |
| What is the current revenue growth of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Zhangzhou Pientzehuang? | Current revenue multiple of Zhangzhou Pientzehuang is 11.0x. |
| Is Zhangzhou Pientzehuang profitable? | Yes, Zhangzhou Pientzehuang is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's last 12 months EBITDA is $512M. |
| What is Zhangzhou Pientzehuang's EBITDA margin? | Zhangzhou Pientzehuang's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Zhangzhou Pientzehuang? | Current EBITDA multiple of Zhangzhou Pientzehuang is 33.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
